- この都医学研セミナーは終了しました。-
演者 | (1)Xinchun Chen, Vice Dean for research, Shenzhen University Medical School, Professr (2)Xingzhi Xu, Executive Dean of Shenzhen University Medical School, Professor |
---|---|
会場 | 対面式(2BC会議室) |
日時 | 2024年2月2日(金曜日) (1)13:15~ (2)16:30~ |
世話人 | 正井 久雄 所長・ゲノム動態プロジェクトリーダー |
参加自由 | 詳細は下記問合せ先まで |
お問い合わせ |
研究推進課 普及広報係 電話 03-5316-3109 |
(1)Tuberculosis remains as severe problem for public health with over 1.4 millions annual killing globally. One challenge for tuberculosis is drug resistance.Host directed therapy(HDT) is promising strategy for overcome drug resistance tuberculosis as it target host instead of pathogen. By defining the key gene in regulating macrophage anti-tuberculosis immunity, we identified several HDT drug candidate for treatment of tuberculosis. We further dissect the mechanism underlying these HDT drug candidate and investigate their potential in treatment of tuberculosis in animal study and/or clinical try.
(2)DNA replication is a complex and systematic process that ensures faithful duplication of the genome and subsequent cell division only once per cell cycle, however, it is constantly challenged by various endogenous and exogenous stressors. Proper DNA replication and replication stress response safeguard the genome stability and integrity. Protein post-translational modifications (PTMs), such as phosphorylation and ubiquitination, are key regulators of the DNA replication stress response. The ataxia-telangiectasia and RAD3-related kinase (ATR)-CLASPIN-checkpoint kinase 1 (CHK1) signaling cascade is a pivotal mechanism that ensures proper response to replication stress. I will present our recent progress how the ATR-CHK1 signaling is regulated and its implication in cancer therapy.